AVITA Therapeutics, Inc. Form 8-K Summary
Business context and reporting period
AVITA Therapeutics, Inc., now identified in the request as AVITA Medical, Inc., filed a current report on September 9, 2020, regarding an event occurring on September 6, 2020. The company’s common stock traded on Nasdaq under the symbol RCEL. The filing does not provide quarterly or annual financial results.
Material event
- Director Damien McDonald notified the Board that he would not stand for re-election at the company’s 2020 annual meeting of stockholders.
- Mr. McDonald was expected to continue serving as a director and as a member of the Audit Committee until his current term expired at the 2020 annual meeting.
- The company stated that his departure was not due to any disagreement with the company concerning its operations, policies, or practices.
Financial metrics and liquidity
The filing does not report revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Outlook, risks, and unusual items
The filing does not provide management guidance, an operating outlook, material risks, contingencies, or unusual financial items. The principal disclosed governance change is the planned departure of a director following the 2020 annual meeting.
Important facts for investors to verify
- Confirm the date and outcome of the 2020 annual meeting and the resulting Board and Audit Committee composition.
- Review subsequent filings for any replacement director appointment or changes to committee membership.
- Consult the company’s periodic reports for financial condition, operating results, liquidity, and business outlook, which are not included in this 8-K.